Acute coronary artery injury in dogs following administration of CI-1034, an endothelin a receptor antagonist

Cardiovascular Toxicology

Volumn 6, Issue 1, 2006, Pages 25-38

  McDuffie, J Eric ^a,b   Yu, Xinwen ^b   Sobocinski, Gregg ^b   Song, Yunling ^b   Chupka, Jonathan ^a   Albassam, Mudher ^b  

^a Esperion Therapeutics Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

CI 1034; Coronary artery injury; Dog; Endothelin receptor antagonism

Indexed keywords

4 (7 ETHYL 1,3 BENZODIOXOL 5 YL) 2 [(2 TRIFLUOROMETHYL)PHENYL] 2H 1,2 BENZOTHIAZINE 3 CARBOXYLATE 1,1 DIOXIDE POTASSIUM; AMYLOID A PROTEIN; BENZOTHIAZINE DERIVATIVE; CASPASE 3; CI 1034; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN A RECEPTOR ANTAGONIST; FIBRINOGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; NITRIC OXIDE; PD 0180988; PROTEIN S 100; PROTEIN S 100A8; UNCLASSIFIED DRUG;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOG; ENZYME DEGRADATION; FIBRINOGEN BLOOD LEVEL; HEART ATRIUM; HEART MUSCLE NECROSIS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MALE; MONOCYTE; MYOCARDITIS; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUNICA MEDIA;

ACUTE DISEASE; ANIMALS; BIOLOGICAL MARKERS; CALGRANULIN A; CALGRANULIN B; CASPASE 3; CASPASES; CORONARY VESSELS; DOGS; FIBRINOGEN; HEART ATRIA; HEMORRHAGE; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; NECROSIS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; RECEPTOR, ENDOTHELIN A; THIAZINES; TUNICA MEDIA;

ANIMALIA; CANIS FAMILIARIS;

EID: 33746384105     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1385/CT:6:1:25     Document Type: Article

References (22)

1. Kirchengast, M. and Luz, M. (2005). Endothelin receptor antagonists clinical realities and future directions. J. Cardiovac. Pharmacol. 45:182-191.
2. Naseem, K.M. (2005). The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 6:33-65.
3. Liu, S., Beckman, J.S., and Ku, D.D. (1994). Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. JPET 268:1114-1121.
4. Horstman, L.L., Jy, W., Jimenez, J.J., and Ahn, Y.S. (2004). Endothelial microparticles as markers of endothelial dysfunction. Front Biosci. 9:1118-1135.
5. Pearson, T.A., Mensah, G.A., Alexander, R.W., et al. (2003). Markers of inflammation and cardiovascular disease: application to clinical and public health practice. Circulation 107:499-511.
6. Joseph, E.C., Jones, H.B., and Kerns, W.D. (1996). Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phosphodiesterase III inhibitor. Toxicol. Pathol. 24:429-435.
7. Albassam, M.A., Metz, A.L., Potoczak, R.E., et al. (2001). Studies on coronary arteriopathy in dogs following administration of CI-1020, an endothelin A receptor antagonist. Toxicol. Pathol. 29:277-284.
8. Metz, A.L., Dominick, M.A., Suchanek, G., and Gough, A.W. (1991). Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. Toxicol. Pathol. 19:98-107.
9. Foell, D., Hernández-Rodríguez, J., Sánchez, M., Vogl, T., Cid, M.C., and Roth, J. (2004). Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis. J. Pathol. 204:311-316.
10. Louden, C., Nambi, P., Branch, C., et al. (1998). Coronary arterial lesions in dogs treated with endothelin receptor antagonist. J. Cardiovasc. Pharmacol. 31(Suppl):S384-S385.
11. Expert Working Group on Drug-Induced Vascular Injury. (2005). Drug-induced vascular injury - a quest for biomarkers. Toxicol. Appl. Pharmacol. 203:62-87.
12. Brott, D., Gould, S., Jones, H., et al. (2005). Biomarkers of drug-induced vascular injury. Toxicol. App. Pharm. 207(Suppl 2):441.
13. Slim, R.M., Song, Y., Albassam, M., and Dethloff, L.A. (2003). Apoptosis and nitrative stress associated with phosphodiesterase inhibitor-induced mesenteric vasculitis in rats. Toxicol. Pathol. 31:638-645.
14. Zhang, J., Herman, E.U., Chadwick, D.P., et al. (2002). SK&F 95654-induced acute cardiovascular toxicity in Sprague-dawley rats-histopathologic, electron microscopic, and immunohistochemical studies. Toxicol. Pathol. 30:28-40.
15. Jones, H.B., Macpherson, A., Betton, G.R., Davis, A.S., Siddall, R., and Greaves, P. (2003). Endothelin antagonist-induced coronary and systemic arteritis in the beagle dog. Toxicol. Pathol. 31:263-272.
16. Louden, C.S., Nambi, P., Pullen, M.A., et al. (2000). Endothelin receptor subtype distribution predisposes coronary arteries to damage. Am. J. Pathol. 157:123-134.
17. Schumacher, A., Seljeflot, I., Sommervoll, L., Christensen, B., Otterstad, J.E., and Arnesen, H. (2002). Increased levels of markers of vascular inflammation in patients with coronary heart disease. Scand. J. Clin. Lab. Invest. 62:59-68.
18. Stephan-Gueldner, M. and Inomata, A. (2000). Coronary arterial lesions induced by endothelin antagonists. Toxicol. Lett. 112-113:531-535.
19. Clemo, F.A., Evering, W.E., Snyder, P.W., and Albassam, M.A. (2003). Differentiating spontaneous from drug-induced vascular injury in the dog. Toxicol. Pathol. 31(Suppl):25-31. Review.
20. Berryman, K.A., Edmunds, J.J., Bunker, A.M., et al. (1998). Endothelin receptor antagonists: synthesis and structure activity relationships of substituted benzothiazine-1,1-dioxides. Bioorg. Med. Chem. 6:1447-1456.
21. USA Food and Drug Administration, Center for Drug Evaluation and Research (2001). Bosentan Advisory Committee, 93rd Meeting, August 10th, 2001, Washington, DC.
22. Verma, S., Shu-Hong, L., Badiwala, M.V., et al. (2002). Endothelin antagonism and interleukin-6 inhibition attenuate the proathrogenic effects of C-reactiveprotein. Circulation 105:1890-1896.